Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.37 |
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15752631 | 0.87 | LNPEP (0.37) | CHRM4ACACBLNPEPCHRM2WNT3A | |
| SCHEMBL15743126 | 0.87 | LRRK2 (0.39) | CHRM4ACACBLNPEPCHRM2LRRK2 | |
| SCHEMBL20376814 | 0.86 | LNPEP (0.36) | CHRM4ACACBLNPEPCHRM2LRRK2 | |
| SCHEMBL15709869 | 0.85 | AOC3 (0.39) | CHRM4ACACBLNPEPCHRM2LRRK2 | |
| SCHEMBL17115674 | 0.81 | LNPEP (0.38) | ACACBLNPEPLRRK2AOC3 | |
| SCHEMBL25914355 | 0.76 | PDE10A (0.42) | — | |
| SCHEMBL15710131 | 0.73 | AOC3 (0.37) | CHRM4ACACBLNPEPCHRM2AOC3 | |
| SCHEMBL17115678 | 0.70 | AOC3 (0.40) | ACACBAOC3 | |
| SCHEMBL18860891 | 0.70 | GLS (0.47) | WNT3A | |
| SCHEMBL20392420 | 0.70 | AOC3 (0.36) | CHRM4ACACBLNPEPCHRM2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015143340-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |